CN112535670A

CN112535670A - Agomelatine dispersible tablet and preparation method thereof

Info

Publication number: CN112535670A
Application number: CN201910897999.7A
Authority: CN
Inventors: 向伟; 王宇杰
Original assignee: Beijing Wanquan Dezhong Medical Biological Technology Co Ltd
Current assignee: Beijing Wanquan Dezhong Medical Biological Technology Co Ltd
Priority date: 2019-09-23
Filing date: 2019-09-23
Publication date: 2021-03-23

Abstract

The invention discloses an agomelatine dispersible tablet and a preparation method thereof. The solubility of the agomelatine in water is only 0.00776 mg/mL, and the prepared dispersible tablet is beneficial to medicine dissolution and improves the bioavailability; the dispersible tablet is prepared by taking agomelatine as a medicinal active ingredient, mixing with Uygur and other appropriate auxiliary materials and adopting a wet granulation technology, so that the bitter tingling stimulation of the agomelatine is covered, the prepared agomelatine dispersible tablet has good taste, is suitable for old, young and patients with swallowing dysfunction, enhances the compliance of the patients, and has certain clinical advantages.

Description

Agomelatine dispersible tablet and preparation method thereof

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of an agomelatine compound and a preparation method of a dispersible tablet of the agomelatine compound.

Background

Depression is an episode of manic depression, with hypoaffect, thought retardation, and speech reduction, with retardation as typical symptoms. Depression seriously disturbs the lives and work of patients, placing a heavy burden on families and society, and about 15% of depression patients die from suicide. A joint study by the world health organization, world bank and harvard university has shown that depression has become the second leading disease burden in china; agomelatine is a drug of a 'heavy bomb' grade in mental diseases, is a new breakthrough in the field of depression treatment, is a melatonin receptor agonist, and is also a 5-hydroxytryptamine 2C (S-HTx) receptor antagonist. Animal tests and clinical studies show that the medicine has the effects of resisting depression, resisting anxiety, regulating sleep rhythm and biological clock, and has adverse reactionLittle, no adverse effect on sexual function, and no withdrawal reaction. The traditional Chinese medicine composition is mainly used for clinically treating adult depression, has quick response, has good curative effects on depression and accompanying symptoms such as anxiety, insomnia and the like, has few adverse reactions and high safety, and provides a new method for clinically treating MDD. Agomelatine (Agomelatine) with chemical name of N- [2- (7-methoxynaphthalen-1-yl) ethyl]Acetamide with molecular formula C₁₅H₁₇NO₂Molecular weight 243.3, solubility in water is only 0.00776 mg/mL. The molecular structural formula is as follows:

agomelatine is developed and developed by Servier company, is approved to be on the market in the European Union in 2009, is approved to be on the market in the SFDA 4 months in 2011, is on the market in China, has the specification of 25mg, is the first melatonin receptor agonist antidepressant, has certain difficulty in treating old, young and patients with swallowing dysfunction in the aspect of administration because of being a film coated tablet, and can improve the medicine taking difficulty of the patients and increase the compliance of the patients when being used as a dispersible tablet; agomelatine has strong bitter and tingling sensation, generates strong stimulating sensation on oral mucosa, has no obvious effect of the conventional flavoring agent, and is coated for improving the mouthfeel of the dispersible tablet; the granule coating belongs to the field of film coating, and the film coating can improve the appearance of the granule, cover up the bitter taste and unpleasant odor of the medicine, weaken the stimulation to gastrointestinal tract, and play a certain role in preventing moisture and isolating air. Meanwhile, the coating material is selected and the coating film formed by the coating liquid prescription is designed, so that the release position, the release time and the release speed of the medicament are controlled, and the effects of constant release, slow release, quick release and targeting are achieved.

Disclosure of Invention

The invention relates to an agomelatine dispersible tablet and a preparation method thereof, agomelatine main drug particles are coated by Eudragit L30D-55 to form an Eudragit L30D-55 coating compound which is used together with other flavoring agents, so that the bitter and pungent taste and the irritation of the raw material agomelatine can be effectively covered, and the compliance of patients can be improved; the prepared dispersible tablet can improve the dissolution speed and the bioavailability of the agomelatine.

The agomelatine dispersible tablet comprises a compound of the bulk drug agomelatine, a filler, a disintegrating agent, a flavoring agent, a lubricant and other pharmaceutically acceptable auxiliary materials. Wherein the weight percentage of the agomelatine compound is 20-65%, the weight percentage of the filling agent is 25-55%, the weight percentage of the disintegrating agent is 0.5-35%, the weight percentage of the adhesive is 0.5-5%, the weight percentage of the flavoring agent is 0.1-30%, and the weight percentage of the lubricating agent is 1-4%.

In the agomelatine main drug particles and the Eudragit L30D-55 coating compound, the weight ratio of the Eudragit L30D-55 to the main drug particles is 5: 100-50: 100.

The preparation process of the agomelatine dispersible tablet comprises the following steps:

(1) mixing: sieving Agomelatine and the internal materials with 80 mesh sieve, and mixing, wherein the filler is one or more of microcrystalline cellulose, lactose monohydrate, starch, sodium carboxymethyl starch, mannitol, lactose, and dextrin; the disintegrant is one or more of carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, croscarmellose sodium and crospovidone, and can be added internally, externally or internally.

(2) And (3) granulating: adding appropriate amount of binder, stirring to obtain soft material, sieving with 40 mesh sieve, granulating, wherein the binder is one or more of corn starch and polyvidone, and the wetting agent is purified water, anhydrous alcohol or mixture thereof.

(3) And (3) drying: drying water in a 50 ℃ oven to be less than 3.0%.

(4) Straightening: and (4) finishing the granules by using a 40-mesh sieve.

(5) Coating: coating the main drug granules by using a fluidized bed and a certain proportion of Eudragit L30D-55 to prepare the agomelatine main drug granules and Eudragit L30D-55 coating compound.

(5) Adding: calculating the added material according to the yield, wherein the correctant is any one or more of fruit essences such as aspartame, acesulfame, menthol, strawberry and the like; the lubricant is one or more of talcum powder, stearic acid, silicon dioxide, magnesium stearate, superfine silica powder and colloidal silicon dioxide, and the adding modes of the lubricant comprise internal addition, external addition and internal and external addition.

(6) Tabletting: the theoretical weight of the tablet is 200mg, and the hardness is 20-40N.

(7) The dispersion uniformity was determined and the dispersion was complete within 3 min.

(8) According to the requirements, the dissolution rate of the prepared dispersible tablet can reach more than 80% in 45 min.

Detailed Description

The following examples further illustrate the benefits of the present invention, and the examples are for illustrative purposes only and do not limit the scope of the present application, and variations and modifications apparent to those of ordinary skill in the art in light of the present application are intended to be included within the scope of the present application.

Example 1

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Microcrystalline cellulose	115.00
		Low-substituted hydroxypropyl cellulose	18.00
Povidone	Proper amount of
		Uttqi L30D-55	23.00
Low substituted hydroxypropyl cellulose (plus)	9.00
		Acesulfame potassium (external)	4.50
Menthol (external)	0.50
		Colloidal silica (plus)	2.00
Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

sieving agomelatine and low-substituted hydroxypropyl cellulose with a 80-mesh sieve, sieving microcrystalline cellulose with a 60-mesh sieve, uniformly mixing, using an aqueous solution of povidone as a binder to prepare a soft material, sieving with a 40-mesh sieve for granulation, drying in an oven at 50 ℃ until the moisture content is lower than 3.0%, sieving with a 40-mesh sieve for size stabilization, coating the particles with a 15% water dispersion of Eudragit L30D-55 in a fluidized bed, drying to obtain an agomelatine compound, calculating an additional material according to the yield, and tabletting.

Example 2

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Mannitol	120.00
		Low-substituted hydroxypropyl cellulose	15.00
Povidone	Proper amount of
		Uttqi L30D-55	15.00
Low substituted hydroxypropyl cellulose (plus)	15.00
		Acesulfame potassium (external)	5.00
Silicon dioxide (addition)	2.00
		Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

agomelatine, mannitol and low-substituted hydroxypropyl cellulose are sieved by a 80-mesh sieve and uniformly mixed, the aqueous solution of povidone is used as a bonding agent to prepare a soft material, the soft material is sieved by a 40-mesh sieve for granulation, the mixture is dried by a 50-DEG C oven until the moisture content is lower than 3.0 percent, the granules are sized by the 40-mesh sieve, the granules are coated by 15 percent Eudragit L30D-55 aqueous dispersion in a fluidized bed, the drying is carried out, the Agomelatine compound is obtained, the additional material is added according to the yield, and the tablet is pressed.

Example 3

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Lactose monohydrate	110.00
		Cross-linked polyvidone	15.00
Povidone	Proper amount of
		Uttqi L30D-55	17.00
Low substituted hydroxypropyl cellulose (plus)	10.00
		Microcrystalline cellulose (plus)	8.00
Acesulfame potassium (external)	10.00
		Colloidal silica (plus)	2.00
Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

sieving agomelatine, lactose monohydrate and crospovidone by a sieve of 80 meshes, uniformly mixing, preparing a soft material by taking the aqueous solution of the povidone as a binding agent, sieving by a sieve of 40 meshes for granulation, drying by an oven at 50 ℃ until the moisture content is lower than 3.0%, grading by the sieve of 40 meshes, coating the granules by adopting an Eudragit L30D-55 aqueous dispersion with the concentration of 15% in a fluidized bed, drying to obtain an agomelatine compound, calculating an additional material according to the yield, and tabletting.

Example 4

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Lactose	100.00
		Cross-linked polyvidone	20.00
Povidone	Proper amount of
		Uttqi L30D-55	30.00
Polyvinylpolypyrrolidone (plus)	10.00
		Strawberry essence (external)	1.00
Acesulfame potassium (external)	9.00
		Silicon dioxide (addition)	2.00
Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

sieving agomelatine, lactose and crospovidone by a sieve of 80 meshes, uniformly mixing, using the aqueous solution of povidone as a bonding agent, preparing a soft material, sieving by a sieve of 40 meshes for granulation, drying by an oven at 50 ℃ until the moisture content is lower than 3.0%, grading by the sieve of 40 meshes, coating the granules in a fluidized bed by using a water dispersion of Eudragit L30D-55 with the concentration of 15%, drying to obtain an agomelatine compound, calculating an additional material according to the yield, and tabletting.

Example 5

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Corn starch	120.00
		Cross-linked polyvidone	15.00
Povidone	Proper amount of
		Uttqi L30D-55	12.00
Carboxymethyl starch sodium (plus)	13.00
		Acesulfame potassium (external)	9.50
Menthol (external)	0.50
		Colloidal silica (plus)	2.00
Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

screening agomelatine, corn starch and crospovidone by using a 80-mesh sieve, uniformly mixing, using a povidone aqueous solution as a binder, preparing a soft material, screening by using a 40-mesh sieve for granulation, drying by using a 50-DEG C oven until the moisture content is lower than 3.0%, screening by using a 40-mesh sieve for granulation, coating the granules by using a 15% Eudragit L30D-55 aqueous dispersion in a fluidized bed, drying to obtain an agomelatine compound, calculating an additional material according to the yield, and tabletting.

Example 6

The prescription composition is as follows:

name of raw and auxiliary materials	1000 tablets (g)
		Agomelatine	25.00
Corn starch	75.00
		Sodium starch glycolate	15.00
Povidone	Proper amount of
		Uttqi L30D-55	15.00
Carboxymethyl starch sodium (plus)	20.00
		Microcrystalline cellulose (plus)	35.00
Acesulfame potassium (external)	10.00
		Silicon dioxide (addition)	2.00
Magnesium stearate (addition)	2.00

The preparation process comprises the following steps:

sieving agomelatine, corn starch and carboxymethyl starch sodium by a sieve of 80 meshes, uniformly mixing, preparing a soft material by taking a water solution of povidone as a bonding agent, sieving by a sieve of 40 meshes, granulating, drying by an oven at 50 ℃ until the moisture is lower than 3.0%, granulating by the sieve of 40 meshes, coating the granules by using a water dispersion of Eudragit L30D-55 with the concentration of 15% in a fluidized bed, drying to obtain an agomelatine compound, calculating an additional material according to the yield, and tabletting.

The results for the samples prepared in examples 1, 2, 3, 4, 5, 6 are specified below:

agomelatine dispersible tablet

Example 1

Example 2

Example 3

Example 4

Example 5

Example 6

Compressibility

Good effect

Appearance of the product

Bright and clean and beautiful

Hardness of

Compliance with regulations

Degree of friability

Compliance with regulations

Uniformity of dispersion

Compliance with regulations

Mean dissolution

92.79%

87.44%

88.12%

96.43%

85.72%

90.76%

Taste of the product

Slightly bitter and cool

Slightly bitter and slightly pungent

No bitter or pungent feeling

Has no bitter and pungent taste, and strawberry flavor

Has no irritation and refreshing feeling

No bitter or pungent feeling

In summary, the following steps: the increase of the dosage of Eudragit L30D-55 can obviously improve and cover the unpleasant taste of agomelatine such as the bitter tingling of agomelatine, and the like, and has no obvious influence on the dissolution of the medicament, in addition, the combined use of the flavoring agent also has the good effect of improving the taste; from the above results, example 4 gave the best results, with an average dissolution of 96.43%, in a fluidized bed with a particle coating, especially a ratio of 21:100 of Lktex L30-30D-55 to the drug substance.

The above examples are only preferred examples to fully illustrate the present application, and are to fully illustrate that the agomelatine bitter tingle irritation is covered by the eudragit L30D-55, the taste is improved, the patient compliance is improved, the drug dissolution is not affected, and certain clinical advantages are achieved, and the scope of protection of the present application is not limited thereto. The equivalent substitution or change made by the person skilled in the art on the basis of the present application is within the protection scope of the present application. The protection scope of this application is subject to the claims.

Claims

1. An agomelatine dispersion comprising: the agomelatine main drug granules, the Eudragit L30D-55 coating compound, a filling agent, a disintegrating agent, a flavoring agent and a lubricating agent.

2. The agomelatine dispersible tablet according to claim 1, wherein the agomelatine main drug particles consist of a filler, a disintegrating agent and an adhesive.

3. The agomelatine dispersible tablet according to claim 1, wherein the weight ratio of agomelatine main drug particles to the Eudragit L30D-55 in the Eudragit L30D-55 coating compound is 5: 100-50: 100.

4. The agomelatine dispersible tablet according to claim 1 to 3, wherein the main drug particles are coated with Eudragit L30D-55, in a coating composition, Eudragit L30D-55, using an alcohol-water dispersion.

5. The agomelatine dispersible tablet according to claim 4, wherein the aqueous alcohol dispersion is Eudragit L30D-55 dispersed in purified water, absolute ethanol or a mixture of both.

6. The agomelatine dispersible tablet according to claim 1-5, wherein the coating compound of the main drug particles and the Eudragit L30D-55 is prepared by applying powder coating method and particle coating method to the main drug particles through the Eudragit L30D-55 pure water dispersion.

7. According to claim 6, the agomelatine compound is prepared by a particle coating method, and fluidized bed coating is adopted.

8. The tablet core group is an agomelatine compound, and comprises a coating agent, a filling agent, an adhesive, a disintegrating agent and the like, a flavoring agent and a lubricating agent are added, the yield is calculated after granulation, and the agomelatine compound is tabletted after the materials are added.

9. The agomelatine dispersible tablet according to claim 1-2, wherein the disintegrant is any one or more of carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, croscarmellose sodium and crospovidone;

the adhesive is one or more of corn starch and polyvidone;

the filler is any one or more of microcrystalline cellulose, lactose monohydrate, starch, sodium carboxymethyl starch, mannitol, lactose and dextrin;

the lubricant is any one or more of talcum powder, stearic acid, silicon dioxide, magnesium stearate, superfine silica powder and colloidal silicon dioxide;

the flavoring agent is any one or more of fruit essences such as aspartame, acesulfame potassium, menthol, strawberry and the like; the wetting agent is purified water, absolute ethyl alcohol or a mixed solution of the purified water and the absolute ethyl alcohol.

10. The agomelatine dispersible tablet comprises the following components in percentage by weight:

agomelatine complex 20%~65% Filler 25%~55% Disintegrating agent 0.5%~35% Flavouring agent 0.1%~30% Adhesive agent 0.5%~5% Lubricant agent 1%~4%

。